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About 50% of male diabetic patients have erectile dysfunction (ED),
which is considered as the vascular and neuropathic complications.
Vascular endothelial growth factor (VEGF) has been extensively
documented for its pathogenic signiﬁcance in different complications
of diabetes andwe reported that VEGF signaling is greatly diminished in
penis in a rat model of type II diabetes. The present study used 3 weeks
duration of streptozotocin (STZ)-induced diabetic (DM) rat model to
assess the VEGF expression with NO system in penile tissue and
concomitantly the effects of endothelin antagonismhas been studied on
these changes. Male Sprague–Dawley rats were administered citrate
saline vehicle or STZ (65 mg/kg IP). One week after the injection,
animals were separated into those receiving endothelin-A/B (ET-A/B)
dual receptor antagonist (SB209670, 1 mg/kg/day), endothelin-A (ET-A)
receptor antagonist (TA-0201, 1 mg/kg/day) or saline for 2 weeks by
osmotic mini pump. The local ET-1 level in DM penis was higher by 20%
than that in non-DM rats. A 30% decrease in VEGF expression in penile
tissue was seen in DM rats. Penile NO and eNOS levels were decreased in
DM rats; greatly restored by ET-A receptor antagonist while unchanged
by ET-A/B dual antagonist. iNOS was not signiﬁcantly changed in penile
tissues among non-DM, DM and ET-A antagonist treated groups. Thus,
we conclude that (1) VEGF and pAkt were downregulated in type 1 DM
penis, and that (2) the ET-A antagonist was potentially effective in
reversing the decreased NO and eNOS levels in DM penis than those by
ET-A/B dual antagonist.
doi:10.1016/j.lfs.2014.01.047
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Aim: To elucidate the pathophysiological signiﬁcance of the endog-
enous oxidized LDL (oxLDL) blocker, which was originally described as
an endothelium-derived secreted protein Del-1 (developmental endo-
thelial locus-1). Background: oxLDL can potentiate the induction of foam
cell formation and inﬂammatory responses, the processes which are
believed to be integral to atherogenesis. However, no endogenous
proteins, which interfere with oxLDL binding to its receptors, have been
identiﬁed. Methods: Interaction between oxLDL and Del-1 was exam-
ined in a cell-free system by ELISA. Inhibition of binding and action of
oxLDL was examined with CHO cells expressing LOX-1 and with COS-7
cells transfected with scavenger receptors. Cultured human umbilical
vein endothelial cells (HUVEC) and THP-1 were also used to analyze the
inhibitory effects of Del-1 on oxLDL action. Results: We found that Del-1
selectively bound to oxLDL, but not to native LDL. Del-1 inhibited the
uptake of DiI-labeled oxLDL (DiI-oxLDL) by LOX-1 expressed in COS-7,
but did not inhibit DiI-labeled native LDL uptake by LDL receptor. Del-1
inhibited DiI-oxLDL binding to other oxLDL receptors aswell, such as SR-
A and CD36. In addition, Del-1 inhibited DiI-oxLDL uptake byHUVEC and
THP-1-derived macrophages. Site-directed mutagenesis revealed that
two arginine residues in Del-1 were crucial for the binding of oxLDL.
Furthermore, Del-1 suppressed oxLDL-induced signal transduction in
LOX-1-expressing CHO cells. In HUVEC, Del-1 also suppressed oxLDL-
induced signaling and endothelin-1 secretion. Thus, we demonstrated
that Del-1 is an endogenous protein which protects cells from oxLDL
actions. Conclusion: We identiﬁed, for the ﬁrst time, an endogenous
oxLDL blocker which may play a regulatory role in interfering
progression of atherosclerosis.
doi:10.1016/j.lfs.2014.01.048
Selective endothelin ETA and dual ETA/ETB receptor blockade
improves endothelial function in patients with type 2 diabetes
and coronary artery disease
John Pernow, Arnar Rafnsson, Alexey Shemyakin
Institution of Medicine, Karolinska Institute, Stockholm, Sweden
E-mail address: John.Pernow@ki.se (J. Pernow)
Purpose: Endothelin-1 contributes to endothelial dysfunction in
patients with atherosclerosis and type 2 diabetes. In healthy arteries the
ETA receptormediates themain part of the vasoconstriction induced by
endothelin-1 while the ETB receptor mediates vasodilatation. The ETB
receptor expression is upregulated in atherosclerosis and may thereby
contribute to the vasoconstrictor tone and development of endothelial
dysfunction. The aim of the present study was to compare the
effects of selective ETA and dual ETA/ETB blockade on endothelial
function in patients with type 2 diabetes and coronary artery disease.
Methods: Twelve patients were included in this cross-over study with
blinded evaluation. Forearm blood endothelium-dependent and endo-
thelium-independent vasodilatation was assessed by venous occlusion
plethysmography during intra-arterial infusions of serotonin and nitro-
prusside, respectively, before and after 60 min of intra-arterial infusion of
either the selective ETA antagonist BQ123 or the combination of BQ123
and the ETB antagonist BQ788. Changes between the two treatments
were compared using 2-way analysis of variance. Results: Dual ETA/ETB
receptor blockade increased baseline forearm blood ﬂow by 30± 14%
(P b 0.01) whereas selective ETA blockade did not (14 ± 8%). Both
selective ETA blockade and dual ETA/ETB blockade induced a 2-fold
increase in endothelium-dependent vasodilatation (P b 0.001). The
improvement in endothelium-dependent vasodilatation did not differ
between the two treatment strategies. Both treatments improved the
endothelium-independent vasodilatation. Conclusions: Both selective
ETA and dual ETA/ETB improve endothelial function in patients with
type 2 diabetes and coronary artery disease. Addition of ETB to ETA
receptor blockade increases basal blood ﬂow but does not additionally
improve endothelial function.
doi:10.1016/j.lfs.2014.01.049
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Background: Statins reduce the incidence of cardiovascular events in
patientswith acutemyocardial infarction (AMI). Although all statins are
equally effective in secondary prevention, there might be certain
differences in the effects of lipophilic and hydrophilic statins and its
associationwith oxidative stress levels in AMI patients remains unclear.
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Therefore, we investigated oxidative stress levels in AMI patients
with lipophilic atorvastatin or hydrophilic pravastatin. Methods and
results: The study population included a prospective, randomized,
open-label, study in AMI patients within ALPS-AMI study. Patients that
have undergone successful percutaneous coronary intervention will be
randomly allocated to receive either atorvastatin or pravastatin with the
treatment goal of lowering their low-density lipoprotein-cholesterol
level below 100mg/dl for 2 years. Diacron-reactive oxygen metabolite
(dROM) and biological antioxidant potential (BAP) levelsweremeasured
in AMI patients with lipophilic (atorvastatin, n = 38) and hydrophilic
(pravastatin, n = 36) statin therapy on admission (dROM: 395.5 ± 37.5
vs. 392.1 ± 35.6 Carratelli units (U. Carr) (p= 0.37), BAP: 2756.3 ± 75.2
vs. 2849.1 ± 71.6 mmol/l (p = 0.39), respectively) and 6, 12, and
24 months (24 months: dROM: 374.5 ± 41.5 vs. 381.1 ± 37.6 U. Carr
(p= 0.28), BAP: 2957.3 ± 135.9 vs. 2941.5 ± 121.3 mmol/l (p= 0.48),
respectively). Conclusion: This is the ﬁrst clinical trial to compare the
effects of lipophilic and hydrophilic statin therapy on oxidative stress
levels and no difference was noted in oxidative stress levels between
lipophilic and hydrophilic statin therapy in patients with AMI during the
follow-up period.
doi:10.1016/j.lfs.2014.01.050
Endothelin-dependent vasoconstrictor activity in metabolically
healthy and unhealthy obese patients
Carmine Cardilloa, Francesca Schinzaria, Angelo Adamoa,
Valentina Rovellab, Manfredi Tesaurob
aDepartment of Internal Medicine, Catholic University Medical School,
Rome, Italy
bDepartment of Internal Medicine, Tor Vergata University, Rome, Italy
E-mail address: carmine.cardillo@rm.unicatt.it (C. Cardillo)
Obesity is associated with higher risk of premature death due to
metabolic and cardiovascular abnormalities. One third of obese
individuals, however, have a “metabolically healthy” phenotype and it
is debated whether this status carries lower cardiovascular risk than its
metabolically unhealthy counterpart. Given the role of the endothelin
(ET)-1 system in the development of obesity-related vascular dysfunc-
tion, we investigated whether differences exist in ET-1-dependent
vasoconstrictor activity between the divergent obesity subphenotypes.
To this end, we compared vasodilator responses (strain-gauge plethys-
mography) to intra-arterial infusion of the selective ETA receptor
blocker BQ-123 (10 nmol/min for 60 min) in healthy subjects (n = 31)
and obese patients (n= 38); obese patients were divided in two
subgroups according to the absence (n= 11) or presence (n= 27) of
any of the glucose or lipid abnormalities characteristic of the metabolic
syndrome (MetS; ATP III criteria). The vasodilator response to BQ-123
was greater in obese than in lean subjects (P b 0.001), whereas no
difference was observed in the response to BQ-123 between metabol-
ically healthy and unhealthy obese patients (P N 0.05). Similarly, BQ-
123-induced vasodilation was related to the number of MetS compo-
nent in the whole population (P = 0.008), but not within the obese
group (P N 0.05). In the whole population, body mass index and mean
arterial pressure were signiﬁcant determinants of the response to BQ-
123 (r = 0.46 and r = 0.42, respectively; both P b 0.001), whereas no
correlation was observed between BQ-123-induced vasodilation and
either plasma glucose, triglycerides or HDL-cholesterol levels (all
P N 0.05). In conclusion, ET-1-dependent vasoconstrictor tone is higher
in obese patients than in their lean counterpart, but this defect is not
inﬂuenced by the presence of obesity-related metabolic abnormalities.
doi:10.1016/j.lfs.2014.01.051
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There is a growing body of evidence suggested that epigallocate-
chin gallate (EGCG), a major catechin isolated from green tea, has
several beneﬁcial effects such as anti-oxidant and anti-inﬂammatory
activities. However, whether treatment with EGCG could suppress the
ET-1-induced contraction in large arteries from type 2 diabetic rats is
unknown. We hypothesized that long-term treatment with EGCG
would attenuate the ET-1-induced contractions in type 2 diabetic
arteries. To test this hypothesis, Otsuka Long–Evans Tokushima fatty
(OLETF) rats (43 weeks old)were treatedwith EGCG (200 mg/kg/day for
2 months, p.o.) and contractile/relaxant responses to ET-1, phenyleph-
rine (PE), acetylcholine (ACh) and sodium nitroprusside (SNP) in the
presence and absence of endotheliumweremeasured in common carotid
artery (CA) and thoracic aorta (TA) from EGCG-treated and -untreated
OLETF rats and control Long–Evans Tokushima Otsuka (LETO) rats. In
OLETF rats, EGCG attenuated sensitivity to ET-1 in CA [pD2, EGCG-
treated: 7.95 ± 0.07 vs. -untreated: 8.15 ± 0.06 (p b 0.05)] and TA [pD2,
EGCG-treated: 7.98 ± 0.08 vs. -untreated: 8.24 ± 0.06 (p b 0.05)] com-
pared to untreated groups. However, EGCG did not alter PE-induced
contractions in both arteries from OLETF rats. In the endothelium-
denuded arteries, EGCG did not affect ET-1- and PE-induced contractions
in both OLETF and LETO groups. ACh-induced relaxations were increased
by EGCG treatment in CA and TA from OLETF group. SNP-induced
relaxations were similar between EGCG-treated and -untreated groups.
Our data suggest that within the timescale investigated here, EGCG
attenuates ET-1-induced contractions in large arteries from type 2
diabetic rats and one of the mechanisms may be attributable to
normalizing endothelial function.
doi:10.1016/j.lfs.2014.01.052
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Background and objective: Previous studies have described an
association between kidney diseases and endothelin. Primary ne-
phrotic syndrome (NS) is the common renal disease in children. The
aim of this study was to determine whether polymorphisms in the
endothelin-A receptor gene might be associated with the morbidity
and the steroid response of primary nephrotic syndrome in children.
Methods: 53 children with primary nephrotic syndrome as case group
were subdivided into steroid resistance NS group and non-steroid
resistance NS group; hypertension group and non-hypertension
group. 50 healthy children were as control group. All subjects were
genotyped for endothelin-A receptor polymorphisms in locus
rs10305936 (in exon 8 of the EDNRA) by using the polymerase chain
reaction and direct gene sequence test technique. Results: (1) There is
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